Although a randomised clinical trial using everolimus as the second-line treatment of advanced HCC did not demonstrate a survival advantage (EVOLVE-1), subsequent studies have highlighted the benefits of mTOR inhibitor in reducing HCC recurrence in post-transplant patients [92–94]. The gene discussed is MTOR; the disease is hepatocellular carcinoma.